Johnson & Johnson Innovative Medicine, the pharmaceutical segment of Johnson & Johnson (formerly named Janssen) has announced a projected investment of EUR 580 million ($620 million) in Italy over the next five years, of which EUR 125 million ($134 million) will support an increase in production capacity. 

The company’s site in Latina, Italy, is part of Johnson & Johnson’s global supply chain network. The site produces more than four billion tablets every year, for about 30 different products, with 97% of its production exported.  

The investment plan will enable a production capacity increase of more than 25%, as it includes projects to support pipeline products and new production technologies, such as a Flex Line, to more efficiently handle the packaging of small production batches and a new continuous manufacturing line.  

Source: Johnson & Johnson